» Articles » PMID: 38436432

Comparison of Perceptions of Skin Condition, Product Use and Allergen Reactivity Between People with Psoriasis and Controls in the European Dermato-Epidemiology Network (EDEN) Fragrance Study

Overview
Specialty Dermatology
Date 2024 Mar 4
PMID 38436432
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriasis, a chronic inflammatory skin disease, goes beyond visible symptoms and affects the general well-being of patients. The aim of this study is to understand how patients with psoriasis perceive their skin characteristics and reactivity to allergens. The study population includes 11,283 participants within the European Dermato-Epidemiology Network (EDEN) Fragrance study, covering several European regions. The study compared perceptions of skin dryness, sensitivity, product avoidance and reactivity to allergens between patients with psoriasis and controls, evaluating the potential influence of psoriasis severity. The results showed that subjects with psoriasis reported dry skin (71.1%) and sensitive skin (49.4%) more often than did controls (51.6% and 38.5%, respectively). Psoriasis patients were more likely to avoid specific products. Interestingly, there were no significant differences in patch-test results between the 2 groups and the severity of psoriasis did not have a consistent impact on these perceptions. In conclusion, people with psoriasis tend to perceive their skin as drier and more sensitive. Notably, the severity of psoriasis did not consistently influence these perceptions and objective reactivity to allergens did not align with subjective perception. Understanding these aspects is crucial for tailoring treatments to improve the well-being of patients with psoriasis, which warrants further research to explore subjective perceptions of skin well-being in patients with psoriasis.

Citing Articles

How Hormonal Balance Changes Lives in Women with Psoriasis.

Cassalia F, Lunardon A, Frattin G, Danese A, Caroppo F, Belloni Fortina A J Clin Med. 2025; 14(2).

PMID: 39860587 PMC: 11766064. DOI: 10.3390/jcm14020582.


Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules.

Ferrara F, Verduci C, Laconi E, Mangione A, Dondi C, Del Vecchio M Antibodies (Basel). 2024; 13(3).

PMID: 39311381 PMC: 11417777. DOI: 10.3390/antib13030076.

References
1.
Naldi L, Cazzaniga S, Goncalo M, Diepgen T, Bruze M, Elsner P . Prevalence of self-reported skin complaints and avoidance of common daily life consumer products in selected European Regions. JAMA Dermatol. 2013; 150(2):154-63. DOI: 10.1001/jamadermatol.2013.7932. View

2.
Martins A, Ascenso A, Ribeiro H, Marto J . The Brain-Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. Cells. 2020; 9(4). PMC: 7226493. DOI: 10.3390/cells9040796. View

3.
Holman D, Kalaaji A . Cytokines in dermatology. J Drugs Dermatol. 2006; 5(6):520-4. View

4.
Langan S, Bouwes Bavinck J, Coenraads P, Diepgen T, Elsner P, Grob J . Update on the activities of the European Dermato-Epidemiology Network (EDEN). Dermatology. 2006; 213(1):1-2. DOI: 10.1159/000092828. View

5.
Iznardo H, Puig L . The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol. 2021; 17(2):187-199. DOI: 10.1080/1744666X.2021.1886081. View